Cystic Fibrosis has seen dramatic advances in treatment since the last edition, including targeted CFTR protein modulators for most CFTR gene abnormalities. This new edition is an update of the rapid clinical and scientific advances in improving prognosis, and the impact of CoVID-19, which has transformed conventional models of care.